Irish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

angiotensin/infarction

Sábháiltear an nasc chuig an gearrthaisce
Leathanach 1 ó 40 torthaí

Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION The present invention relates to the use of angiotensin I derivatives, including des-Aspartate angiotensin I in the treatment and/or prevention of infarction-related cardiac injuries and disorders. More particularly, the present invention contemplates a method for the

Use of angiotensin II receptor antagonists for treating acute myocardial infarction

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
The enzyme cascade of the renin-angiotensin system (RAS) comprises a series of biochemical events and, as is well known, there are a variety of approaches for using regulatory intervention to open up treatment possibilities, for example treatment of hypertension. Angiotensinogen, an

Use of angiotensin II receptor antagonists for treating acute myocardial infarction

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
The enzyme cascade of the renin-angiotensin system (RAS) comprises a series of biochemical events and, as is well known, there are a variety of approaches for using regulatory intervention to open up treatment possibilities, for example treatment of hypertension. Angiotensinogen, an
The invention relates to novel 1-(p-thienylbenzyl)imidazoles of formula (I), ##STR2## which are potent agonists of angiotensin (1-7) receptors and, because of the production land release of the vasorelaxant, antithrombotic, and cardio-protective messengers cyclic 3',5'-guanosine monophosphate (cGMP)
The invention relates to novel 1-(p-thienylbenzyl)imidazoles of formula (I), ##STR2## which are potent agonists of angiotensin (1-7) receptors and, because of the production hand release of the vasorelaxant, antithrombotic, and cardio-protective messengers cyclic 3',5'-guanosine monophosphate (cGMP)

Substituted triazoles as angiotensin II inhibitors

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION This invention relates to novel compounds of the following formulae: ##STR1## The invention also relates to pharmaceutical compositions comprising a compound of the invention as the active ingredient, a method of treating a physiological condition in mammals that is mediated

Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION Angiotensin-converting-enzyme (ACE) inhibitors have been shown to reduce morbidity and mortality in patients with chronic heart failure and systolic left ventricular dysfunction as well as in patients post myocardial infarction. (See The CONSENSUS Trial Study Group.

Use of inhibitors of the renin-angiotensin system

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION This invention relates to the use of inhibitors of the renin-angiotensin system. BACKGROUND OF THE INVENTION Wasting diseases may be categorised into generalised and localised wasting diseases. To deal first with generalised wasting, many disease processes can lead to

Use of inhibitors of the renin-angiotensin system

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION This invention relates to the use of inhibitors of the renin-angiotensin system. BACKGROUND OF THE INVENTION Wasting diseases may be categorised into generalised and localised wasting diseases. To deal first with generalised wasting, many disease processes can lead to

Use of inhibitors of the renin-angiotensin system

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION This invention relates to the use of inhibitors of the renin-angiotensin system. BACKGROUND OF THE INVENTION Wasting diseases may be categorised into generalised and localised wasting diseases. To deal first with generalised wasting, many disease processes can lead to

Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to methods and compositions for treating fibrosis. More particularly, the invention relates to the use of angiotensin inhibitors in combination with nitric oxide stimulators to inhibit the progression of fibrosis. 2.

Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to methods and compositions for treating fibrosis. More particularly, the invention relates to the use of angiotensin inhibitors in combination with nitric oxide stimulators to inhibit the progression of fibrosis. 2.

Fused heterocyclic compounds, having angiotensin II antagonistic activity

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION The present invention relates to novel fused heterocyclic compounds having potent pharmacological actions and intermediates for the preparation thereof. More particularly, the present invention relates to fused heterocyclic compounds having potent anti-hypertensive activity
TECHNICAL FIELD This invention relates generally to pharmaceutical formulations for treating patients at elevated cardiovascular risk, and more particularly relates to dosage forms that combine a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin. BACKGROUND Many
FIELD OF THE INVENTION The present invention relates to a novel combination of an ADP-receptor blocking antiplatelet drug, such as clopidogrel, and an antihypertensive drug, for example, an angiotensin II antagonist such as irbesartan, or an ACE inhibitor such as fosinopril, or a NEP/ACE inhibitor
Bí ar ár
leathanach facebook

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht

  • Oibreacha i 55 teanga
  • Leigheasanna luibhe le tacaíocht ón eolaíocht
  • Aitheantas luibheanna de réir íomhá
  • Léarscáil GPS idirghníomhach - clibeáil luibheanna ar an láthair (ag teacht go luath)
  • Léigh foilseacháin eolaíochta a bhaineann le do chuardach
  • Cuardaigh luibheanna míochaine de réir a n-éifeachtaí
  • Eagraigh do chuid spéiseanna agus fanacht suas chun dáta leis an taighde nuachta, trialacha cliniciúla agus paitinní

Clóscríobh symptom nó galar agus léigh faoi luibheanna a d’fhéadfadh cabhrú, luibh a chlóscríobh agus galair agus comharthaí a úsáidtear ina choinne a fheiceáil.
* Tá an fhaisnéis uile bunaithe ar thaighde eolaíoch foilsithe

Google Play badgeApp Store badge